Knowledge Exchange by ISID

Dengue Vaccine Confidence and Vaccine Hesitancy
  • Speaker: Aslam Khan (USA)
  • Facilitated & Produced by: Amador (Tino) Delamerced (USA)
  • March 1, 2024

Learning Objectives:


  • How are dengue viruses transmitted? Which populations are most at risk of contracting dengue?
  • What do current prevention strategies for dengue look like? Are there particularly effective interventions outside of vaccination?
  • What are the different types of DENV? Do they produce different forms of disease? Are certain DENV types more common than others?
  • Does infection with one virus type reduce the risk of infection from other types? Would vaccination help patients who have had dengue infection before?
  • What are the currently available vaccines? Can you talk about the effectiveness of CYD-TDV (Dengvaxia)? Why is CYD-TDV not recommended for people who do not have dengue seropositivity?
  • What are the components of the TAK-003 vaccine? How is it different from CYD-TDV? What is the efficacy of the TAK-003 vaccine?
  • For how long do these vaccinations provide immunity?
  • Is there a sense of confidence level the general public has in these dengue vaccines? How much dengue vaccination hesitancy has been observed?
  • What is the cost of the vaccines?
  • Within the DENV space, are there any areas of study that you are keeping an eye on and interested in seeing develop?
This podcast is supported by an unrestricted educational grant from Takeda.
Scientific Updates Around Dengue
  • Speaker: Aslam Khan (USA)
  • Facilitated & Produced by: Amador (Tino) Delamerced (USA)
  • March 1, 2024

Learning Objectives:


  • What is the estimated burden of dengue disease worldwide?  In which areas of the world is the burden of dengue the greatest?
  • What is the WHO 1997 classification of dengue? How did the 2009 WHO revised classification scheme address criticisms of the original 1997 classification scheme? Are there newer revisions to the classification scheme of dengue infections?
  • What are the symptoms of DENV infections? What are the “warning signs” of more severe disease? What are the phases of infection?
  • How is dengue diagnosed? What else do you keep on the differential?
  • Do certain virus types of dengue cause more severe disease than others? Which populations tend to have more severe disease?
  • How is dengue treated?
This podcast is supported by an unrestricted educational grant from Takeda.
Antimicrobial Updates
  • Speaker: Afreenish Amir (Pakistan)
  • Facilitated & Produced by: Amador (Tino) Delamerced (USA)
  • December 15, 2023

This podcast covers innovations in tackling AMR with a discussion of AI solutions, advanced diagnostics, newer treatments, and vaccines in AMR.

This podcast is supported by an unrestricted educational grant from bioMerieux.
Exploring Solutions: Insights from One Health's Leading Experts
  • Chair: Dr. Lucille Blumberg
  • Speaker: Prof. Wanda Markotter
  • Speaker: Prof. Alessandra Scagliarini
  • Speaker: Dr. Jennifer Bloodgood

This webinar is designed for researchers, healthcare professionals, students, and anyone passionate about the critical intersection of infectious diseases, human health, and environmental health.

Chikungunya Vaccines Development
  • Chair: Fingani Mphande-Nyasulu, Thailand
  • Speaker: Diana Rojas Alvarez (Switzerland)
  • September 26, 2023

Chikungunya virus (CHIKV) has been identified as a priority pathogen and as an emerging infectious disease requiring special action by the World Health Organization (WHO). Its reemergence is rapid and geographically extensive, it has caused large outbreaks with high attack rates in Africa, Asia, Europe, Americas, and islands in the Indian and Pacific Oceans. 
Although Chikungunya fever is a self-limiting disease and the associated fatality rate is low, chikungunya-related death has been reported in certain populations, specially in people with pre-existing conditions.

Since there is no specific treatment, there is a medical need for prophylaxis against CHIKV infection. Some promising preclinical and clinical vaccine candidates have been developed during recent years, involving a wide range of technology platforms including: inactivated Viruses and Subunit Vaccines, Live-Attenuated Viruses, Virus-Like Particles, Viral Vector Vaccines and Nucleic Acid-Based Vaccines. Advancing developments in current candidates in the pipeline as well as further R&D work required is crucial as it is understanding the epidemiological gaps and modeling needs to perform further efficacy trials; in this webinar some of these aspects will be presented and questions welcomed from the audience.

This webinar is supported by an unrestricted educational grant from Valneva.
The Value of a Multidisciplinary Approach to Sepsis Management
  • Chair: Jaffar Al-Tawfiq (Saudi Arabia)
  • Co-Chair: Vrinda Nampoothiri (India)
  • Speakers: Nesrine Rizk (Lebanon), Saleh Zein-El-Dine (Lebanon), and Imad Bou Akl (Lebanon)
  • September 12, 2023

Sepsis is the body’s extreme response to an infection. Despite recent progress in the understanding and treatment of sepsis, few data or recommendations exist that detail effective approaches to sepsis care in resource-limited low-income and middle-income countries. Although few data exist on the burden of sepsis in LMICs, the prevalence of HIV and other comorbid conditions in some LMICs suggest that sepsis is a substantial contributor to mortality in these regions. In well-resourced countries, sepsis management relies on protocols and complex invasive technologies not widely available in most LMICs. However, key concepts and components of sepsis management are potentially translatable to resource-limited environments. Health personnel in LMICs should learn how to recognize sepsis and the importance of early and appropriate antibiotic use and laboratory diagnosis of sepsis. Simple and low-cost standardized laboratory testing should be emphasized to allow accurate diagnosis, prognosis, and monitoring of treatment response. Evidence-based interventions and treatment algorithms tailored to LMIC ecology and resources should thus be developed and validated.

This webinar is supported by an unrestricted educational grant from bioMerieux.
Treatment Strategies for Dengue Infection
  • Chair: Neelika Malavige (Sri Lanka)
  • Co-Chair: Muhammed Niyas (India)
  • Speakers: Ashley St. John (Singapore) and Eng Eong Ooi (Singapore)
  • July 25, 2023

Dengue is a public health problem that continues to increase globally. Dengue is spreading to new areas, including Europe, with some countries reporting first-time local transmission cases. As treatment options are limited, public health control measures include strengthening national programs to meet objectives through coordinated efforts inside and outside the health sector. There is currently no definitive treatment for dengue; only supportive treatment is available for patients with the infection.

However, there have been recent advances in the development of promising drugs for dengue therapeutics, including direct antivirals and host-targeted drugs for reducing inflammation and vascular pathologies. Developing novel vector control methods and new approaches to case management are important for prevention and control. A safe and efficacious vaccine remains the foundation of a comprehensive countermeasure strategy. Recent advances in host-targeted pathways and novel therapeutic approaches are crucial and should be integrated into the research agenda with current vector control tools and vaccination developments.

This webinar is supported by an unrestricted educational grant from Takeda.
Chikungunya: Forecasting, Risk Mapping and Clinical Trials
  • Chair: Nicola Petrosillo (Italy)
  • Co-Chair: Theresa Ochoa (Peru)
  • Speakers: Assaf Anyamba (USA) and Lin Chen (USA)
  • March 28, 2023

Chikungunya is a mosquito transmitted alpha virus. Since its emergence in Africa, the global distribution is rapidly expanding, the disease has spread to most continents. The spread to new areas is possible due to the travel of infected persons and presence of mosquitoes in these new areas that are able to spread the disease. The spread has been found to be more in tropical and sub-tropical countries. Several data driven empirical approaches and spatiotemporal forecasting have been used to forecast chikungunya spread in places like the Americas. Some of these forecasting methods have been used to predict infected cases and locations based on machine learning. Although there is currently no specific treatment and vaccine in use, there are several vaccine candidates in different stages of clinical trials that have shown promising results.

Please take 2 minutes after the webinar to fill out our evaluation form:

This webinar is supported by an unrestricted educational grant from Valneva.
Emergence of Chikungunya: Distribution and Vector Ecology
  • Chair: Helena Maltezou (Greece)
  • Co-Chair: Laura Talarico (Argentina)
  • Speakers: Alfonso Rodriguez-Morales (Colombia), Nicola Petrosillo (Italy), and Kenneth Linthicum (USA)
  • December 13, 2022

Chikungunya is a mosquito borne viral disease caused by the Chikungunya virus (CHIKV), a Togaviridae virus, and is transmitted by Aedes mosquitoes. Clinical symptoms include acute onset of fever, debilitating joint and muscle pain, headache, nausea, and rash, potentially developing into long-term serious health impairments. Chikungunya virus causes clinical illness in 72 – 92% of infected human around 4 to 7 days after an infected mosquito bite. Complications resulting from the disease include visual, neurological, heart and gastrointestinal manifestations; fatalities have been reported in elderly people at higher risk.
Chikungunya outbreaks have been reported in Asia, Africa, the Americas and recently in Europe. Both the medical and economic burden are expected to grow as the CHIKV primary mosquito vectors continue their geographic spread Although there are some candidate vaccines in clinical trials none are licensed. Therefore, chikungunya shall remain a major public health threat.

This webinar is supported by an unrestricted educational grant from Valneva.
We found no results for your search. Please change or remove at least one filter to broaden your search.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies